A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer.

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2014

At a glance

  • Drugs Retaspimycin (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 16 May 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 31 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Apr 2014, as per ClinicalTrials.gov record.
    • 25 Sep 2013 Top-line results published in an Infinity Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top